Toxicity and survival results of a phase II study investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma

Strahlentherapie und Onkologie

Volumn 181, Issue 10, 2005, Pages 652-659

  Beşe, Nuran Şenel ^a,b   Büyükünal, Evin ^a   Özgüroǧlu, Mustafa ^a   Demir, Gökhan ^a   Yildirim, Ayşe ^a   Mandel, Nil Molinas ^a   Demirelli, Fuat ^a   Serdengeçti, Süheyla ^a   Öber, Ahmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chemoradiotherapy; Gastric adenocancer; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINATE CALCIUM; LEVAMISOLE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HEMOGLOBINOPATHY; HUMAN; HUMAN TISSUE; LEUKOCYTE DISORDER; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY; STOMACH ADENOCARCINOMA; SURVIVAL RATE; THROMBOCYTE DISORDER; TREATMENT PLANNING;

ADENOCARCINOMA; ADULT; AGED; COBALT RADIOISOTOPES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 26444541632     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1399-2     Document Type: Article

References (33)

1. Arcangeli G, Saracino B, Arcangeli A, et al. Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2002;54:1069-75.
2. Bleiberg H, Goffin JC, Dalesio O, et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer: a randomized trial of the Gastro-intestinal Tract Cancer Cooperative Group of the EORTC. Eur J Surg Oncol 1989;15:535-43.
3. Bogner L, Scherer J, Treutwein M, et al. Verification of IMRT: techniques and problems. Strahlenther Onkol 2004;180:340-50.
4. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
5. Burch PA, Keppen MD, Schroeder G. North Central Cancer Treatment Group phase II study of fluorouracil and high dose levamisole for gastric and gastroesophageal cancer using survival as the primary end of efficacy. Am J Clin Oncol 1999;22:505-8.
6. Choi JS, Lee KH, Ahn MJ, et al. A randomised trial comparing cisplatin plus 5-fluorouracil or without levamisole in operable gastric cancer. Korean J Intern Med 1997;12:155-62.
7. Cox JD, Stetz J, Pajak T. Toxicity criteria of the Radiation Therapy Oncology Group RTOG and the European Organisation for Research and Treatment of Cancer EORTC. Int J Radiat Oncol Biol Phys 1995;31:1341-6.
8. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522-30.
9. De Meerleer G, Vakaet L, De Gersem W, et al. Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 2004;180:136-43.
10. Falcone A. Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 2003;14:Suppl 2:45-7.
11. Fleming ID, Cooper JS, Henson DE, et al. Stomach. In: AJCC staging manual, 5th edn. Philadelphia: Lippincott-Raven, 1997:71-6.
12. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
13. Gez E, Sulkes A, Yablonsky-Peretz T, et al. Combined 5-fluorouracil 5-FU and radiation therapy following resection of locally advanced gastric carcinoma. J Surg Oncol 1986;31:139-42.
14. Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983;9:965-75.
15. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a reoperation series second or symptomatic. Clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
16. Hattori T, Niimoto M, Toge T, et al. Effects of levamisole in adjuvant immunochemotherapy for gastric cancer; a prospective randomized controlled study. Jpn J Surg 1983;13:460-85.
17. Hehr T, Adamek HE. Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma. Strahlenther Onkol 2002;178:164-6.
18. Henning GT, Schild SE, Stafford SL, et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2000;46:589-98.
19. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastic carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-32.
20. The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988;75:1100-4.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc B 1958;53:457-81.
22. Klautke G, Foitzik T, Ludwig K, et al. Neoadjuvant radiotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 2004;180:695-700.
23. Landry J, Tepper JE, Wood WC, et al. Analysis of survival and local control following surgery for gastric cancer. Int J Radiat Oncol Biol Phys 1990;19:1357-62.
24. Lohr F, Dobler B, Mai S, et al. Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 2003;179:557-63.
25. Macdonald JS, Smalley SR, Benedetti J, et al. Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach of gastroesophageal junction. N Engl J Med 2001;345:725-30.
26. Miwa H, Orita K. Immunochemotherapy with levamisole for stage III gastric cancer patients. Acta Med Okayama 1983;36:483-91.
27. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
28. Nimoto M, Hattori T, Ito I, et al. Levamisole in postoperative adjuvant immunochemotherapy of gastric cancer. A randomized controlled study of the MMC Tegafur regimen with or without levamisole. Report I. Cancer Immunol Immunother 1984;18:13-8.
29. Park SH, Kim DY, Hoe JS, et al. Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 2003;14:1373-7.
30. Regine WF, Mohiuddin M. Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 1992;24:921-927.
31. Sauer R. The re-evaluation of radiochemotherapy in resectable stomach carcinoma. Strahlenther Onkol 2000;176:343.
32. Tepper JE, O'Connell MJ, Petroni GR, et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 1997;15:2030-9.
33. Wakui A, Kikuchi K, Yokoyama M, et al. Phase III multicenter study of levamisole LMS - a randomized evaluation in advanced gastrointestinal cancer, special reference to stomach cancer. Gan To Kagaku Ryoho 1983;10:1610. abstract.